Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Checkpoint Race Takes Turn With BMS’ New Lung Trial, Merck’s Rolling Melanoma BLA

Executive Summary

Bristol-Myers Squibb’s launch of a new Phase III lung cancer study of nivolumab monotherapy in those with high expression of PD-L1 lung cancer patients raises questions about the role of the biomarker and the possibility of combination therapy with Yervoy. The PD-L1 biomarker is still being evaluated and strategies are likely to differ depending on drug and tumor type.


Related Content

Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss
Two Approaches To PD-1 Blocker Pediatric Studies Could Help Clarify Biomarker’s Role
Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts